polyethylene glycol-recombinant human megakaryocyte growth and development factor

Known as: PEG-rHuMGDF, Polyethylene Glycosylated Recombinant Human MGDF, PEG Recombinant Human Megakaryocyte Growth and Development Factor 
A pegylated formulation containing a recombinant growth factor with thrombopoietic activity. The recombinant human megakaryocyte growth and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2016
05101519952016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Chronic immune thrombocytopenic purpura (ITP) is manifested by autoantibody-induced platelet destruction. Platelet turnover… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2002
2002
We conducted a phase 1-2 clinical trial to evaluate the effect of pegylated recombinant human megakaryocyte growth and… (More)
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Clinical trials of thrombopoietin (TPO), the central regulator of megakaryocytopoiesis, have revealed few side effects associated… (More)
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Thrombocytopenia developed in some individuals treated with a recombinant thrombopoietin (TPO), pegylated recombinant human… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2000
2000
The effects of thrombopoietic stimulation on megakaryocytopoiesis, platelet production, and platelet viability and function were… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
1998
1998
Previous studies have shown that daily multiple administration of pegylated recombinant human megakaryocyte growth and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1997
Highly Cited
1997
BACKGROUND Polyethylene glycol (PEG)-conjugated recombinant human megakaryocyte growth and development factor (MGDF, also known… (More)
Is this relevant?
1997
1997
Thrombocytopenia caused by chemotherapy is an important cause of morbidity and mortality in the treatment of malignant disease… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1997
1997
This report examines the effects on hematopoietic regeneration of pegylated recombinant human megakaryocyte growth and… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1996
1996
The in vivo effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated… (More)
Is this relevant?